Abstracts tagged "Rheumatoid arthritis (RA)"

Abstract Number: 490 • 2017 ACR/ARHP Annual Meeting
Clinical and Biomarker Factors in the Prediction of Future Inflammatory Arthritis in ACPA Positive Subjects without Inflammatory Arthritis at Baseline
John P. Gerstenberger¹, Colin I. O'Donnell², Sarah L. Dill³, Randall Tagg⁴, Masoud Asadi-Zeydabadi⁴, M. Kristen Demoruelle⁵, V. Michael Holers⁶ and Kevin D. Deane⁷, ¹Department of Medicine, University of Colorado Denver School of Medicine, Aurora, CO, ²University of Colorado Denver School of Medicine, Aurora, CO, ³Division of Rheumatology, University of Colorado Denver School of Medicine, Aurora, CO, ⁴Department of Physics, University of Colorado Denver, Denver, CO, ⁵1775 Aurora Ct, 1775 Aurora Ct, Aurora, CO, ⁶Rheumatology Division, University of Colorado School of Medicine, Aurora, CO, ⁷Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Antibodies to citrullinated protein antigens (ACPA) can identify individuals who may develop future inflammatory arthritis (IA) and classifiable rheumatoid arthritis (RA). Indeed, there are…
Abstract Number: 1407 • 2017 ACR/ARHP Annual Meeting
Huntingtin Interactin Protein 1 (HIP1) Regulates Invasiveness, Actin Filament and Lamellipodia Formation in Rheumatoid Arthritis Fibroblast-like Synoviocytes (FLS)
Teresina Laragione, Carolyn Harris, Erjing Gao and Percio S. Gulko, Medicine/Rheumatology, Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: Huntingtin-interacting protein 1 (Hip1) is an arthritis severity and joint damage gene recently discovered in rodent models of arthritis. Hip1 regulates fibroblast-like synoviocytes (FLS)…
Abstract Number: 2457 • 2017 ACR/ARHP Annual Meeting
Sarilumab for the Treatment of Active, Moderate-to-Severe Rheumatoid Arthritis (RA): An Analysis of Cost per Effectively Treated Patient
Marie Fournier¹, Chieh-I Chen², Andreas Kuznik², Clare Proudfoot³, Usha Mallya⁴ and Kaleb Michaud⁵, ¹Sanofi France, Chilly-Mazarin, France, ²Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ³Formerly of Sanofi, Guildford, United Kingdom, ⁴Sanofi, Bridgewater, NJ, ⁵University of Nebraska Medical Center, Omaha, NE
Background/Purpose: The MONARCH study (NCT02332590) evaluated monotherapy with sarilumab 200 mg subcutaneous (SC) + placebo every 2 weeks (Q2W) versus adalimumab 40 mg SC +…
Abstract Number: 125 • 2017 ACR/ARHP Annual Meeting
Exposure to Passive Smoking and RA Risk; Results from a Swedish Case-Control Study
Lars Alfredsson¹, Anna Karin Hedström² and Lars Klareskog³, ¹The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ²Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ³Dept. of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Smoking has consistently been associated with increased risk of developing rheumatoid arthritis (RA). We investigated the influence of passive smoking on the risk of…
Abstract Number: 495 • 2017 ACR/ARHP Annual Meeting
Efficacy of Tofacitinib in Patients with Moderate to Severe Rheumatoid Arthritis By Baseline C-Reactive Protein Levels and Erythrocyte Sedimentation Rates
Sergio Schwartzman¹, Ronald F van Vollenhoven², Alan K Matsumoto³, Dana Orange⁴, Shweta Shah⁵, Ryan DeMasi⁵, Haiyun Fan⁵, Palle Dahl⁶, Ann Wouters⁷ and Edward C. Keystone⁸, ¹Hospital for Special Surgery, New York, NY, ²Karolinska Institute, Stockholm, Sweden, ³Arthritis & Rheumatism Associates, Wheaton, MD, ⁴Rockefeller University; Hospital for Special Surgery; and New York Genome Center, New York, NY, ⁵Pfizer Inc, Collegeville, PA, ⁶Pfizer Inc, Ballerup, Denmark, ⁷Pfizer Inc, New York, NY, ⁸University of Toronto, Toronto, ON, Canada
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. This post-hoc analysis investigated the impact of inflammation severity at baseline (BL)…
Abstract Number: 1408 • 2017 ACR/ARHP Annual Meeting
The Cation Channel TRPV2 Decreases Rheumatoid Arthritis Fibroblast-like Synoviocyte Invasiveness By Inhibiting RhoA Activation, Cell Adhesion and Actin Cytoskeleton Changes
Teresina Laragione, Carolyn Harris, Erjing Gao and Percio S. Gulko, Medicine/Rheumatology, Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: We have recently identified the non-selective cation channel TRPV2 (transient receptor potential vanilloid subfamily, type 2 channel) as a new central mediator of arthritis…
Abstract Number: 2463 • 2017 ACR/ARHP Annual Meeting
Golimumab in Biologic-NaïVe Patients with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) or Ankylosing Spondylitis (AS) – Subanalysis from a Non-Interventional Evaluation in Germany
Klaus Krüger¹, Gerd R. Burmester², Siegfried Wassenberg³, Martin Bohl-Buehler⁴ and Matthias H. Thomas⁵, ¹Praxiszentrum St. Bonifatius München, München, Germany, ²Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Free University and Humboldt University Berlin, Berlin, Germany, ³Rheumazentrum Ratingen, Ratingen, Germany, ⁴Friedrich-Ebert-Str. 35, Rheumahaus, Potsdam, Germany, ⁵Medical Affairs, MSD Sharp & Dohme GmbH, Bünde, Germany
Background/Purpose: Golimumab (GLM) has demonstrated efficacy and safety in several randomized clinical trials with biologic-naïve patients (pts.). However, more data regarding the effectiveness and patient-reported…
Abstract Number: 131 • 2017 ACR/ARHP Annual Meeting
What Does It Mean to Have Rheumatoid Arthritis Now? a Current Burden of Disease Assessment in the United States
Rebecca Schumacher¹, A Dominique², Sofia Pedro¹, TA Simon² and Kaleb Michaud^1,3, ¹National Data Bank for Rheumatic Diseases, Wichita, KS, ²Bristol-Myers Squibb, Princeton, NJ, ³University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Known since 1859, RA is the most common inflammatory joint disease with 0.5-1% worldwide prevalence. Currently, there is a larger number of medications and…
Abstract Number: 514 • 2017 ACR/ARHP Annual Meeting
BMS-986195, a Novel, Rapidly Acting, Covalent Inhibitor of Bruton’s Tyrosine Kinase: Safety, Pharmacokinetic and Pharmacodynamic Profiles in Healthy Participants
IM Catlett, L Wei, N Zheng, A Liu, B He, I Girgis and M Nowak, Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: Bruton’s tyrosine kinase (BTK) is an attractive, novel therapeutic target for autoimmune disease, as it is required for signal transduction and activation via B-cell…
Abstract Number: 1436 • 2017 ACR/ARHP Annual Meeting
Therapeutic Drug Monitoring on Rheumatoid Arthritis Patients with Reduced Doses of Intravenous Tocilizumab
Virginia Ruiz-Esquide¹, Carla Bastida², Mariona Pascal³, Jordi Yagüe³, Dolors Soy² and Raimon Sanmartí¹, ¹Rheumatology Service, Hospital Clínic de Barcelona, Barcelona, Spain, ²Pharmacy Service, Hospital Clínic de Barcelona, Barcelona, Spain, ³Immunology Service, Hospital Clínic de Barcelona, b, Spain
Background/Purpose: Tocilizumab (TCZ) is an effective treatment for rheumatoid arthritis (RA). There is great variability in intravenous (iv) TCZ serum concentrations among individuals. Moreover, initial…
Abstract Number: 2468 • 2017 ACR/ARHP Annual Meeting
Efficacy of Sarilumab in Patients with Rheumatoid Arthritis Who Previously Received Sarilumab or Tocilizumab
Paul Emery¹, Hubert van Hoogstraten², Shyamalie Jayawardena², Erin K. Mangan³, Paula Cejas⁴ and Patrick Verschueren⁵, ¹NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ²Sanofi Genzyme, Bridgewater, NJ, ³Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁴Hospital Quirónsalud Infanta Luisa, Sevilla, Spain, ⁵Division of Rheumatology, University Hospital Leuven, Leuven, Belgium
Background/Purpose: ASCERTAIN (NCT01768572) was a 24-week, randomized, double-blind, double-dummy, parallel-group, 3-arm, safety study in patients with RA and inadequate response to or intolerance of TNF…
Abstract Number: 132 • 2017 ACR/ARHP Annual Meeting
Occupational Physical Workload and Development of Anti-Collagen Type II Antibodies in Rheumatoid Arthritis Patients
Pingling Zeng¹, Lars Alfredsson², Lars Klareskog³, Mohammed Mullazehi⁴, Saedis Saevarsdottir⁵, Camilla Bengtsson⁶ and Johan Rönnelid⁷, ¹Institute of Environmental Medicine, Institute of Environmental Medicine, Karolinska Institute, Stockholm, Sweden, Stockholm, Sweden, ²The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ³Dept. of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ⁴Department of Immunology, Genetics and Pathology,Uppsala University, Uppsala, Sweden, Uppsala, Sweden, ⁵Karolinska Institute and Karonlinska University Hospital, Stockholm, Sweden, ⁶Inst of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ⁷Department of Immunology Genetics and Pathology, Uppsala University, Uppsala, Sweden
Background/Purpose: We have previously observed an association between exposure to occupational physical workload (PW) and risk of developing rheumatoid arthritis (RA)[1].We posit that PW could…
Abstract Number: 526 • 2017 ACR/ARHP Annual Meeting
Comparative Pulmonary Safety of Abatacept and Tumor Necrosis Factor Inhibitors in Patients with RA and Chronic Pulmonary Condition
Eun Ha Kang¹, Yinzhu Jin², Sara Dejene³, Gregory Brill³, Rishi J. Desai², Jeffrey A. Sparks⁴ and Seoyoung C. Kim⁵, ¹Division of Rheumatology, Department of Internal Medicine, Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea, Republic of (South), ²Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Rheumatology, Immunology and Allergy; Pharmacoepidemiologyand Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Patients with rheumatoid arthritis (RA) can have various pulmonary comorbidities including asthma, chronic obstructive pulmonary disease (COPD) and interstitial lung disease (ILD). Biologics can…
Abstract Number: 1453 • 2017 ACR/ARHP Annual Meeting
Impact of Biological and Targeted Synthetic Dmards on Work in Patients with Chronic Inflammatory Arthritides : A Meta Analysis of Randomized Controlled Trials and Controlled Cohorts
Charlotte Traverson¹, Amandine Tubery¹, Charlotte Hua², Françoise Barchechath-Flaisler¹, Cédric Lukas³, Bernard Combe², Jacques Morel² and Cécile Gaujoux-Viala⁴, ¹Rheumatology, Nîmes University Hospital, Nîmes, France, ²Rheumatology, CHU Lapeyronie and Montpellier University, Montpellier, France, ³Rheumatology, CHU Lapeyronie and EA2415, Montpellier University, University of Montpellier, France, ⁴Rheumatology, Nîmes University Hospital and EA2415 Montpellier University, Nîmes, France
Background/Purpose: The addition of biological (b) and new targeted synthetic (ts) DMARDs agents in chronic inflammatory arthritides (CIAs) therapeutic strategies has improved the possibility of…
Abstract Number: 2470 • 2017 ACR/ARHP Annual Meeting
Efficacy of Sarilumab in Combination with Csdmards in Patients with Rheumatoid Arthritis and Inadequate Response to TNF Inhibitors By Baseline Levels of Disease Activity
Roy Fleischmann¹, Hubert van Hoogstraten², Shyamalie Jayawardena², Erin K. Mangan³, Daniel Ching⁴ and Gerd R. Burmester⁵, ¹Metroplex Clinical Research Center, University of Texas Southwestern Medical Center, Dallas, TX, ²Sanofi Genzyme, Bridgewater, NJ, ³Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁴Timaru Medical Specialists Ltd, Timaru, New Zealand, ⁵Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Free University and Humboldt University Berlin, Berlin, Germany
Background/Purpose: Sarilumab is a human mAb blocking the IL-6Rα. In the phase 3 TARGET study (NCT01709578), sarilumab (150 or 200 mg subcutaneously every 2 weeks…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].